ClinicalTrials.Veeva

Menu

Application of Oral Bacteriotherapy to Promote Anal HPV Clearance in HIV Positive Individuals (HPVinHIV)

U

University of Roma La Sapienza

Status

Unknown

Conditions

HIV
Anal Dysplasia

Treatments

Dietary Supplement: Vivomixx
Other: Placebo

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Published studies suggest that oral probiotic intake can promote the clearance of HPV genital infection and HPV related genital dysplasia in HIV negative women. In the present randomized, double blind, placebo controlled study, investigators will evaluate the ability of oral bacterio-therapy to enhance the clearance of anal HPV infection and anal HPV related dysplasia in HIV infected subjects.

Participants will be evaluated for anal HPV infection and anal dysplasia before and after a 6 months course of daily investigational product intake (Viviomixx® or placebo). HPV infection rate and presence of dysplasia at baseline and at the end of the study will be compared.

Full description

Squamous Cell Carcinoma (SCC) of the anus and the anal canal represents a major concern for the HIV infected population, with incidence rates in the different sub populations (women, men, MSM) that are grater than those observed for other common neoplasms in the same HIV negative sub-populations. Nowadays, screening for anal precancerous dysplasia has been included in most national and international HIV management guidelines; in particular, italian guidelines suggest to screen for the presence of HPV related dysplasia:

  • HIV+ MSM
  • All individuals with previous or current evidence of ant-genital condyloma
  • Women with cytology abnormalities on cervical Pap-smear Since no direct anti-HPV drug is currently available and control or clearance of the infection is possible only trough the effect of immune response, interest is addressed to find strategies to promote spontaneous clearance of infection.

In published studies, oral bacterio-therapy demonstrated the ability to promote HPV clearance and HPV related dysplasia regression in HIV negative women.

In the present randomized, double blind, placebo controlled trial, 40 HIV infected individuals with HPV related anal dysplasia will be enrolled.

At baseline participants will undergo:

  • anal HPV research and identification
  • anal cytology
  • anal brushing for evaluation of local inflammatory milieu and microbiota

Subjects with identified HPV anal infection and anal dysplasia will undergo High Resolution Anoscopy (HRA).

During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.

Participants will then undergo 6 months of oral supplementation with probiotics (Vivomixx®) or placebo.

At the end of the supplementation period (Vivomixx or placebo), participants will undergo:

  • anal HPV research and identification
  • anal cytology
  • anal brushing for evaluation of local inflammatory milieu and microbiota
  • HRA

During HRA, extra biopsies of identified abnormal areas and biopsies of normal mucosa will be obtained. Extra biopsies will be used to investigate the distribution of intra-epithelial immune cells populations.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HIV infected individuals >18 years old
  • stable and effective antiretroviral therapy since at least 12 months
  • HPV associated anal dysplasia
  • patient willing to provide written informed consent

Exclusion criteria

  • impossibility to intake the investigational product
  • any contraindication to blood sampling
  • inflammatory bowel disease
  • use of antibiotics during the 3 months prior to the enrollment in the study
  • pregnancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

40 participants in 2 patient groups, including a placebo group

Oral Bacteriotherapy Arm
Experimental group
Description:
Individuals in this study arm will undergo 6 months of daily intake of an oral probiotic formulation (Vivomixx: 4 sachets/day, each sachet containing 450 billion live bacteria). Probiotic sachets are indistinguishable from placebo
Treatment:
Dietary Supplement: Vivomixx
Placebo Arm
Placebo Comparator group
Description:
Individuals in this study arm will undergo 6 months of daily intake of placebo (4 sachets/day). Placebo sachets are indistinguishable from probiotic
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Eugenio Nelson Cavallari, MD; Gabriella d'Ettorre, Professor, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems